Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies

 
• By Nielsen Hobbs
  
sunrise over Greece
WITH AN INTERCHANGABLE DESIGNATION TO Abbvie’s HUMIRA, BOEHRINGER INGELHEIM’S CYLTEZO COULD HEARLD THE DAWN OF A NEW ERA FOR BIOSIMILARS IN THE US. • Source: Alamy

More from Approvals

More from Product Reviews